Vitiligo
☆ AI Dermatology — Free Service
U rezultatima Stiftung Warentest-a za 2022. iz Njemačke, zadovoljstvo potrošača ModelDerm-om bilo je samo nešto niže nego s plaćenim telemedicinskim konsultacijama.
U rezultatima Stiftung Warentest-a za 2022. iz Njemačke, zadovoljstvo potrošača ModelDerm-om bilo je samo nešto niže nego s plaćenim telemedicinskim konsultacijama.
Vitiligo na prstima je teže liječiti nego na drugim područjima. Osim što je kozmetički neugledan, vitiligo je benigno i nije zarazno. U dermatologiji je najefikasniji tretman fototerapija ili laserski tretman (excimer), koji se primjenjuje 2‑3 puta sedmično, najmanje godinu dana. Ako ne možete često ići u bolnicu iz financijskih razloga ili zato što ste zauzeti, možete isprobati aparat za fototerapiju koji je odobren za kućnu upotrebu.
Vitiligo očnih kapaka
Vitiligo na ruci
relevance score : -100.0%
ReferencesVitiligo je uobičajen kožni poremećaj koji uzrokuje mrlje bijele boje zbog gubitka melanocita. Najnovija istraživanja pokazuju da se radi o autoimunoj bolesti. Iako se često smatra kozmetičkim problemom, može duboko utjecati na mentalno zdravlje i svakodnevni život. Godine 2011. stručnjaci su klasifikovali tip pod nazivom segmentalni vitiligo odvojeno od ostalih.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Pacijenti s aktivnim vitiligom imaju nekoliko terapijskih opcija, kao što su sistemski glukokortikoidi, fototerapija i sistemski imunosupresivi. Pacijenti sa stabilnim vitiligom mogu pronaći olakšanje uz primjenu lokalnih kortikosteroida, lokalnih inhibitora kalcineurina, fototerapije i transplantacijskih procedura. Nedavni napredak u razumijevanju osnovnih procesa vitiliga doveo je do razvoja ciljanih terapija. Trenutno su JAK inhibitori najperspektivniji, nudeći dobru podnošljivost i funkcionalne rezultate, uprkos riziku od aktivacije latentnih infekcija i sistemskih nuspojava koje su uobičajene kod drugih imunosupresiva. Tekuća istraživanja imaju za cilj identificirati ključne citokine uključene u razvoj vitiliga (IFN‑γ, CXCL10, CXCR3, HSP70i, IL‑15, IL‑17/23, TNF). Blokiranje ovih citokina pokazalo je obećavajuće rezultate u životinjskim modelima i kod nekih pacijenata. Pored toga, u toku su istraživački radovi na miRNA‑baziranim terapijama i adoptivnoj Treg‑ćelijskoj terapiji.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Ne postoji poznat lijek za vitiligo. Za osobe sa svijetlom kožom, krema za sunčanje i šminka su najčešće preporučene. Druge opcije liječenja mogu uključivati steroidne kreme ili fototerapiju.
○ Tretman
#Phototherapy
#Excimer laser
#Tacrolimus ointment